IBD – Medxy AI

Decoding Systemic Inflammation in Long COVID and Autoimmune Diseases: The Role of Intestinal Flagellin and the TLR5-IL-15-ARA Axis

By MedXY 08/22/2026

This article explores how intestinal flagellin drives systemic inflammation via the TLR5-IL-15-ARA pathway in long COVID, rheumatoid arthritis, ankylosing spondylitis, and IBD, highlighting potential therapeutic targets and biomarkers.

Gastroenterology news Rheumatology

Unraveling the Gut-Lung Axis: Intestinal Flagellin as a Driver of Multisystem Inflammation via the TLR5-IL-15-ARA Pathway

By MedXY 08/21/2026

Flagellated gut bacteria activate TLR5 on neutrophils, triggering IL-15 release and macrophage arachidonic acid production, driving systemic inflammation in long COVID, rheumatoid arthritis, ankylosing spondylitis, and IBD.

Gastroenterology news

International Consensus on Measuring and Repairing the Gut Barrier in IBD: Practical guidance for clinical trials

By Zhang Paul 07/23/2026

Introduction Inflammatory bowel diseases (IBD)—ulcerative colitis (UC) and Crohn’s disease (CD)—are characterized by chronic intestinal…

Clinical Updates Gastroenterology news Specialties

Elevated Colorectal Cancer Risk in Patients with IBD and Primary Sclerosing Cholangitis: Insights from a National Swedish Cohort

By MedXY 07/30/2025

Patients with inflammatory bowel disease (IBD), particularly those with primary sclerosing cholangitis (PSC) or early-onset disease, face a substantially increased risk of colorectal cancer (CRC), emphasizing the need for vigilant surveillance.